AOL2d
What is Compounded Tirzepatide? Here's What You Need to Know
Tirzepatide is the active ingredient in the FDA-approved versions of the drug, Mounjaro and Zepbound, which are made by the ...
FDA Says Shortage of Eli Lilly’s Zepbound Is Over, but Gives Compounders a Grace Period
The Food and Drug Administration said Thursday that the longstanding shortage of Eli Lilly’s weight-loss drug Zepbound and ...
Is Eli Lilly Stock a Buy?
Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...
FiercePharma9d
FDA reaffirms decision to erase Eli Lilly's tirzepatide from shortage list, halting future flow of knockoffs
The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...
The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
Off-brand versions of Lilly weight loss drug must be pulled off market, could mean higher prices
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
FDA says Lilly weight loss drug shortage is over after taking a second look
The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli ...
STAT9d
FDA confirms shortage of weight loss drug tirzepatide is over, gives compounders a grace period
The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put ...
FiercePharma8d
Lilly's Zepbound scores 2nd approval with landmark FDA nod in obstructive sleep apnea
Christmas has come early for Eli Lilly this year, courtesy of a fresh FDA approval for the Indianapolis drugmaker’s obesity ...
Eli Lilly ‘commends’ ITC ruling cracking down on unlawful tirzepatide imports
In a win for patients, the judge overseeing Lilly’s International Trade Commission case determined that U.S. Customs ...
Eli Lilly to end 2024 among best in Big Pharma; Novo among worst
As the year draws to a close, Wall Street is set to crown Eli Lilly (NYSE:LLY) among the best in Big Pharma, while Novo ...
Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now
The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...